NOVAVAX INC (NVAX)
US6700024010 - Common Stock
We assign a fundamental rating of 2 out of 10 to NVAX. NVAX was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of NVAX have multiple concerns. NVAX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
NVAX had negative earnings in the past year.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
In the past 5 years NVAX reported 4 times negative operating cash flow.
1.2 Ratios
NVAX has a Return On Assets of -16.63%. This is amongst the best in the industry. NVAX outperforms 80.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.63% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX's Gross Margin of 63.79% is amongst the best of the industry. NVAX outperforms 80.78% of its industry peers.
NVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVAX has more shares outstanding than it did 1 year ago.
NVAX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NVAX has been reduced compared to a year ago.
2.2 Solvency
NVAX has an Altman-Z score of -3.76. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX has a Altman-Z score of -3.76. This is comparable to the rest of the industry: NVAX outperforms 43.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.76 |
ROIC/WACCN/A
WACC10.46%
2.3 Liquidity
A Current Ratio of 0.93 indicates that NVAX may have some problems paying its short term obligations.
NVAX has a worse Current ratio (0.93) than 88.61% of its industry peers.
NVAX has a Quick Ratio of 0.93. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX has a Quick ratio of 0.93. This is amonst the worse of the industry: NVAX underperforms 87.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.52%, which is quite impressive.
The Revenue for NVAX has decreased by -15.68% in the past year. This is quite bad
The Revenue has been growing by 95.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.68%
Revenue 1Y (TTM)-15.68%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Sales Q2Q%-54.8%
3.2 Future
The Earnings Per Share is expected to grow by 17.98% on average over the next years. This is quite good.
The Revenue is expected to decrease by -12.75% on average over the next years. This is quite bad
EPS Next Y73.69%
EPS Next 2Y41.96%
EPS Next 3Y29.51%
EPS Next 5Y17.98%
Revenue Next Year-32.58%
Revenue Next 2Y-25.9%
Revenue Next 3Y-13.71%
Revenue Next 5Y-12.75%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NVAX is valuated quite expensively with a Price/Forward Earnings ratio of 100.12.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 91.64% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, NVAX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 100.12 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 29.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.96%
EPS Next 3Y29.51%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVAVAX INC
NASDAQ:NVAX (12/24/2024, 7:28:52 PM)
Premarket: 8.49 -0.02 (-0.24%)8.51
-0.13 (-1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.64%
Inst Owner Change13.67%
Ins Owners0.3%
Ins Owner Change3.32%
Market Cap1.36B
Analysts76.67
Price Target17.75 (108.58%)
Short Float %25.97%
Short Ratio7.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.4%
Min EPS beat(2)-40.73%
Max EPS beat(2)5.92%
EPS beat(4)2
Avg EPS beat(4)-61.61%
Min EPS beat(4)-214.89%
Max EPS beat(4)5.92%
EPS beat(8)5
Avg EPS beat(8)-26.55%
EPS beat(12)5
Avg EPS beat(12)-98.18%
EPS beat(16)6
Avg EPS beat(16)-79.7%
Revenue beat(2)1
Avg Revenue beat(2)0.58%
Min Revenue beat(2)-11.17%
Max Revenue beat(2)12.33%
Revenue beat(4)1
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-11.29%
Max Revenue beat(4)12.33%
Revenue beat(8)3
Avg Revenue beat(8)6.56%
Revenue beat(12)4
Avg Revenue beat(12)-4.95%
Revenue beat(16)5
Avg Revenue beat(16)-3.4%
PT rev (1m)0%
PT rev (3m)-13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-182.78%
EPS NY rev (1m)-76.68%
EPS NY rev (3m)-44.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-76.41%
Revenue NY rev (1m)-10.16%
Revenue NY rev (3m)-7.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 100.12 | ||
| P/S | 1.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.26
EYN/A
EPS(NY)0.08
Fwd EY1%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS5.53
BVpS-3.29
TBVpS-4.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.63% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.79% | ||
| FCFM | N/A |
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.72% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | -3.76 |
F-Score4
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)300.93%
Cap/Depr(5y)410.08%
Cap/Sales(3y)5.06%
Cap/Sales(5y)7.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.68%
EPS Next Y73.69%
EPS Next 2Y41.96%
EPS Next 3Y29.51%
EPS Next 5Y17.98%
Revenue 1Y (TTM)-15.68%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Sales Q2Q%-54.8%
Revenue Next Year-32.58%
Revenue Next 2Y-25.9%
Revenue Next 3Y-13.71%
Revenue Next 5Y-12.75%
EBIT growth 1Y52.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.77%
EBIT Next 3Y27.97%
EBIT Next 5YN/A
FCF growth 1Y84.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.82%
OCF growth 3YN/A
OCF growth 5YN/A